Facilitating effects of valproate on reconsolidation of fear extinctio
- Conditions
- Not Applicable
- Registration Number
- KCT0009483
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 92
Participants provided with an explanation of the study and written consent.
- Participants with uncorrected visual acuity of -8.0 to -2.0 diopters (no restrictions for corrected vision with glasses or lenses).
- Participants not currently having administered any treatment medication and in physical health.
- Carefully considered group of Biolamin Tablet: patients currently taking L-dopa, patients with hyperoxaluria, or pregnant or lactating women.
- Individuals with hypersensitivity to polyvitamin (with vitamine B1, B2, B6, B12, C, or E)
- Individulas not classified as healthy subjects through clinical examination.
- Individuals with organic brain damage or a history of head and neck trauma.
- Patients currently undergoing psychiatric treatment or with a psychiatric history.
- Individuals anticipating surgery or procedures which could interfere the study procedures.
- Carefully considered and contraindicated group of Promag Tablet: patients with liver disease or impairment, renal failure or low protein levels, blood clotting disorders or low platelet count, a history of bone marrow damage or potential patients, or currently pregnant or potentially pregnant women.
- Individuals with a history of adverse reactions to valproate.
- Individuals with difficulty in oral mication intake.
- Researchers directly involved in the present clinical study, researchers' families, employees of the research institution, and their families.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method